Overview

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

To explore the whole-brain anatomical and functional abnormalities in drug-naive patients with schizophrenia ,drug-naive patients with BD, drug-naive patients with MDD and healthy controls by using a combination of cross-sectional and longitudinal study designs, including a longitudinal study with 8 weeks of drugs treatment. And explore whether there are shared imaging biomarkers between these three common mental disorders.

Phase:

N/A

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Central South University

Treatments:

Antipsychotic Agents
Paroxetine

Criteria

Inclusion Criteria:

- Diagnostic criteria for schizophrenia,bipolar disorder, major depressive disorder
according to the Structural Clinical Interview for Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV)

- Never received any treatment before.

- For healthy controls: their first-degree relative had no history of psychiatric
disorders.

Exclusion Criteria:

- The exclusion criteria for all subjects were as follows: any physical illnesses, such
as liver, kidney, and cardiovascular diseases; any current or past neuropsychiatric
disorders; any traumatic brain injury; seizures; serious impulsive behavior; drug or
alcohol addiction; contraindications for MRI; and pregnancy.